Pathos AI Signs Two Major Breast Cancer Drug Licensing Deals Worth Over $2B, Plans $3B Series E

Aug 4, 2026

Pathos AI has expanded its oncology pipeline by securing two major breast cancer drug licensing deals. The company entered a global licensing agreement with Alphamab Oncology for JSKN016, a bispecific antibody-drug conjugate, in a deal valued at up to $2.093 billion, including a $125 million upfront payment. Additionally, Pathos AI partnered with AstraZeneca to clinically develop AZD4241, a preclinical estrogen receptor degrader. Pathos AI will leverage its proprietary Foundry AI platform to optimize clinical trials and patient selection for both therapies.

JSKN016 licensing agreement

▪Pathos AI entered into a global licensing agreement with Alphamab Oncology for the experimental drug JSKN016 on August 3, 2026.
▪Alphamab Oncology is eligible to receive development and commercialization milestone payments from Pathos AI totaling up to $2.093 billion.
▪Under the licensing agreement, Alphamab Oncology will receive a non-refundable upfront payment of $125 million from Pathos AI.
▪Pathos AI acquired the rights to research, develop, manufacture, and commercialize JSKN016 globally, excluding mainland China, Hong Kong, Macau, and Taiwan.

Foundry AI platform

▪Pathos AI will use its Foundry platform to guide patient selection, dosing, and clinical trial design for the breast cancer drug AZD4241.
▪Pathos AI's proprietary Foundry platform utilizes thousands of parallel AI agents to analyze biological, clinical, and real-world data for drug development.
▪Pathos AI utilized its Foundry platform to identify and prioritize the licensing of the JSKN016 drug candidate.

JSKN016 drug profile

▪JSKN016 is conjugated via site-specific glycosylation to achieve a stable drug-to-antibody ratio of 4.
▪JSKN016 is undergoing a Phase 3 clinical trial in China for the treatment of triple-negative breast cancer.
▪JSKN016 is a first-in-class bispecific antibody-drug conjugate designed to target both TROP2 and HER3 receptors on tumor cells.

Pathos AI clinical pipeline

▪The addition of JSKN016 expands Pathos AI's clinical pipeline to four assets, including pocenbrodib, DO-2, and AZD4241.
▪Pathos AI entered into a co-exclusive licensing agreement with AstraZeneca to advance the preclinical estrogen receptor degrader AZD4241 into clinical trials.
▪AZD4241 is an investigational oral therapy designed to degrade both normal and mutated forms of the estrogen receptor in breast cancer.